JP2017533930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533930A5 JP2017533930A5 JP2017525799A JP2017525799A JP2017533930A5 JP 2017533930 A5 JP2017533930 A5 JP 2017533930A5 JP 2017525799 A JP2017525799 A JP 2017525799A JP 2017525799 A JP2017525799 A JP 2017525799A JP 2017533930 A5 JP2017533930 A5 JP 2017533930A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- group
- compound according
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(c1ncc(c(C)c2)[n]1cc2F)N*([C@]1OCCNC1)=O Chemical compound CC(C)(c1ncc(c(C)c2)[n]1cc2F)N*([C@]1OCCNC1)=O 0.000 description 2
- HXURTEIOFRHBEW-UHFFFAOYSA-N CC(C)(c1c(C)nc2[n]1cccc2)NCC1OCCNC1 Chemical compound CC(C)(c1c(C)nc2[n]1cccc2)NCC1OCCNC1 HXURTEIOFRHBEW-UHFFFAOYSA-N 0.000 description 1
- FWKQHNSCMPHIIX-UHFFFAOYSA-N CC(C)(c1nc(C)c2[n]1cccc2C)NC(C1OCCNC1)=O Chemical compound CC(C)(c1nc(C)c2[n]1cccc2C)NC(C1OCCNC1)=O FWKQHNSCMPHIIX-UHFFFAOYSA-N 0.000 description 1
- AZEHTHBKDYOBBQ-AWEZNQCLSA-N CC(C)(c1nc(C2CC2)c2[n]1cccc2C)NC([C@H]1OCCNC1)=O Chemical compound CC(C)(c1nc(C2CC2)c2[n]1cccc2C)NC([C@H]1OCCNC1)=O AZEHTHBKDYOBBQ-AWEZNQCLSA-N 0.000 description 1
- FPHMOSOQACAAJX-ZDUSSCGKSA-N CC(C)(c1nc(C2CC2)c2[n]1cccc2F)NC([C@H]1OCCNC1)=O Chemical compound CC(C)(c1nc(C2CC2)c2[n]1cccc2F)NC([C@H]1OCCNC1)=O FPHMOSOQACAAJX-ZDUSSCGKSA-N 0.000 description 1
- UKIHWFHDMYMUGP-UHFFFAOYSA-N CC(C)(c1nnc2[n]1cccc2C)NC(C1OCCNC1)=O Chemical compound CC(C)(c1nnc2[n]1cccc2C)NC(C1OCCNC1)=O UKIHWFHDMYMUGP-UHFFFAOYSA-N 0.000 description 1
- NSZPVWFCWJFEFI-UHFFFAOYSA-N Cc1ccc[n]2c1cnc2C1(CCC1)NC(C1OCCNC1)=O Chemical compound Cc1ccc[n]2c1cnc2C1(CCC1)NC(C1OCCNC1)=O NSZPVWFCWJFEFI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193185 | 2014-11-14 | ||
| EP14193185.7 | 2014-11-14 | ||
| PCT/EP2015/076440 WO2016075240A1 (en) | 2014-11-14 | 2015-11-12 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533930A JP2017533930A (ja) | 2017-11-16 |
| JP2017533930A5 true JP2017533930A5 (cg-RX-API-DMAC7.html) | 2019-04-25 |
| JP6641367B2 JP6641367B2 (ja) | 2020-02-05 |
Family
ID=51904765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525799A Active JP6641367B2 (ja) | 2014-11-14 | 2015-11-12 | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）アゴニストとしてのモルホリンおよび１，４−オキサゼパンアミド |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10071974B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3218372B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6641367B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170082632A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108592B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015345070A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017009595A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2965566A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2017001181A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA032104B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL251465A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX370366B (cg-RX-API-DMAC7.html) |
| PH (1) | PH12017500821A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016075240A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (cg-RX-API-DMAC7.html) | 2014-01-24 | 2018-02-24 | ||
| EP3053452A1 (en) * | 2015-01-16 | 2016-08-10 | Interquim, S.A. | Naturally derived colour stabilizer |
| JP2019522039A (ja) * | 2016-07-29 | 2019-08-08 | インスメッド インコーポレイテッド | 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11136312B2 (en) | 2017-05-12 | 2021-10-05 | Board of Trustees of the Southern Illinois University | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| US11912687B2 (en) | 2017-05-12 | 2024-02-27 | Board of Trustees of the Southern Illinois University | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| ES3011730T3 (en) | 2018-03-01 | 2025-04-08 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| TWI834637B (zh) | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
| EP3823627A4 (en) | 2018-07-17 | 2022-04-20 | Insmed Incorporated | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY |
| AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
| CN113717161B (zh) * | 2020-05-21 | 2023-06-09 | 广州费米子科技有限责任公司 | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
| WO2022012534A1 (zh) * | 2020-07-13 | 2022-01-20 | 广州费米子科技有限责任公司 | 含氮杂环化合物、药物组合物和应用 |
| AR127055A1 (es) | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
| WO2024148308A1 (en) | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025027049A1 (en) | 2023-08-02 | 2025-02-06 | Boehringer Ingelheim International Gmbh | (2s,5r)-5-(hydroxymethyl)morpholine-2-carboxamides as agonists of sstr4 |
| WO2025247982A1 (en) | 2024-05-29 | 2025-12-04 | Grünenthal GmbH | Piperazines which act as sstr4 modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538124T1 (de) * | 2004-11-12 | 2012-01-15 | Bristol Myers Squibb Co | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| AU2012226375B2 (en) | 2011-03-10 | 2017-04-13 | Lupin Atlantis Holdings Sa | Substituted morpholines as modulators for the calcium sensing receptor |
-
2015
- 2015-11-12 AU AU2015345070A patent/AU2015345070A1/en not_active Abandoned
- 2015-11-12 EA EA201791058A patent/EA032104B1/ru not_active IP Right Cessation
- 2015-11-12 CA CA2965566A patent/CA2965566A1/en not_active Abandoned
- 2015-11-12 US US15/526,361 patent/US10071974B2/en active Active
- 2015-11-12 CN CN201580062239.4A patent/CN107108592B/zh active Active
- 2015-11-12 EP EP15793840.8A patent/EP3218372B1/en active Active
- 2015-11-12 BR BR112017009595A patent/BR112017009595A2/pt not_active Application Discontinuation
- 2015-11-12 KR KR1020177016161A patent/KR20170082632A/ko not_active Withdrawn
- 2015-11-12 MX MX2017006231A patent/MX370366B/es active IP Right Grant
- 2015-11-12 JP JP2017525799A patent/JP6641367B2/ja active Active
- 2015-11-12 WO PCT/EP2015/076440 patent/WO2016075240A1/en not_active Ceased
-
2017
- 2017-03-30 IL IL251465A patent/IL251465A0/en unknown
- 2017-05-04 PH PH12017500821A patent/PH12017500821A1/en unknown
- 2017-05-10 CL CL2017001181A patent/CL2017001181A1/es unknown
-
2018
- 2018-07-30 US US16/048,665 patent/US10577336B2/en active Active